Clotting Time in Transfemoral PCI Linked to Bleeding Risk

Share this content:
Clotting Time in Transfemoral PCI Linked to Bleeding Risk
Clotting Time in Transfemoral PCI Linked to Bleeding Risk

WEDNESDAY, June 27, 2018 (HealthDay News) -- Higher maximal activated clotting time (ACT) is associated with a greater risk of major bleeding after transfemoral (TF) percutaneous coronary intervention (PCI) than after transradial (TR) PCI, according to a study published in June in JACC: Cardiovascular Interventions.

David Louis, M.D., from Brown University in Providence, Rhode Island, and colleagues related maximal ACT to the risk of major bleeding in 14,634 patients undergoing TR or TF PCI with unfractionated heparin monotherapy. They also performed secondary analyses to relate maximal ACT to composites of in-hospital death, myocardial infarction, or stroke and in-hospital death, myocardial infarction, or urgent target vessel revascularization.

The researchers found that more major bleeding occurred at ACT > 290 versus ≤ 290 seconds after TF PCI (7.7 versus 5.8 percent; P = 0.006) but not TR PCI (1.7 versus 2.4 percent; P = 0.18). The findings for major bleeding risk remained significantly higher at ACT > 290 versus ≤ 290 seconds among TF (odds ratio, 1.28; 95 percent confidence interval, 1.02 to 1.62; P= 0.036) but not TR PCI (odds ratio, 0.72; 95 percent confidence interval, 0.42 to 1.22; P = 0.22) after adjustment. There was no association between maximal ACT and incidence of the composite outcomes after TF or TR PCI.

"Higher maximal ACT is associated with a greater risk of major bleeding following TF than TR PCI, conclude the authors.

One author disclosed ties to the medical device industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Moves to Restrict Flavored E-Cig Sales, Ban Menthol Cigarettes

FDA Moves to Restrict Flavored E-Cig Sales, Ban ...

The move stops short of the full ban on e-cigarettes that had been expected

Name-Brand Medications Driving Spike in U.S. Drug Spending

Name-Brand Medications Driving Spike in U.S. Drug Spending

Greatest costs for Humira, Remicade, Enbrel, Novolog, and Neulasta

is free, fast, and customized just for you!




Already a member?

Sign In Now »